Skip to main content

Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the “Life Sciences” Category

Written by Customer Service on . Posted in Public Companies.

MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation Award in the “Life Sciences” category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021.

Every year, the ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) gala rewards Quebec-based companies for leadership in innovation in their respective field.

At the beginning of 2021, Theratechnologies received the United States Food and Drug Administration’s “Fast-track” designation for TH1902 as a single agent for the treatment of patients with advanced and recurrent solid tumors expressing the sortilin receptor and refractory to standard treatments. TH1902 is the lead peptide-drug conjugate derived from the SORT1+ Technology™ in oncology.

“It is quite rare to obtain the “fast-track” designation this early in the drug development process and this was achieved through spectacular preclinical data. We are very proud of this achievement and look forward to the future with great hope for patients,” said Mr. Paul Lévesque, President and Chief Executive Officer of Theratechnologies.

About TH1902
TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This peptide-drug conjugate is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

The Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), contributes a total of 1.4 million dollars towards some of the research currently being conducted for the development of Theratechnologies’ targeted oncology platform.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .

For media and investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
514 336-7800
communications@theratech.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.